Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are mutated in a variety of cancers to confer a gain-of-function activity resulting in the accumulation of an oncometabolite, D-2-hydroxyglutarate (2-HG). Accumulation of 2-HG can result in epigenetic dysregulation and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Urban, Daniel J., Martinez, Natalia J., Davis, Mindy I., Brimacombe, Kyle R., Cheff, Dorian M., Lee, Tobie D., Henderson, Mark J., Titus, Steven A., Pragani, Rajan, Rohde, Jason M., Liu, Li, Fang, Yuhong, Karavadhi, Surendra, Shah, Pranav, Lee, Olivia W., Wang, Amy, McIver, Andrew, Zheng, Hongchao, Wang, Xiaodong, Xu, Xin, Jadhav, Ajit, Simeonov, Anton, Shen, Min, Boxer, Matthew B., Hall, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630632/
https://www.ncbi.nlm.nih.gov/pubmed/28986582
http://dx.doi.org/10.1038/s41598-017-12630-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630632/
https://www.ncbi.nlm.nih.gov/pubmed/28986582
http://dx.doi.org/10.1038/s41598-017-12630-x

Ejemplares similares